Persica Pharmaceuticals Presents New PP353 Data Supporting Non-Opioid Chronic Low Back Pain Treatment
London, UK – July 24, 2026 Persica Pharmaceuticals has presented new scientific analyses supporting the development of its investigational...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
London, UK – July 24, 2026 Persica Pharmaceuticals has presented new scientific analyses supporting the development of its investigational...
